Odyssean LLC raised its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Free Report) by 81.1% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 122,087 shares of the biopharmaceutical company’s stock after acquiring an additional 54,675 shares during the quarter. Ultragenyx Pharmaceutical comprises approximately 0.7% of Odyssean LLC’s holdings, making the stock its largest position. Odyssean LLC owned about 0.12% of Ultragenyx Pharmaceutical worth $4,076,000 at the end of the most recent quarter.
Several other hedge funds also recently modified their holdings of the business. Parallel Advisors LLC lifted its stake in shares of Ultragenyx Pharmaceutical by 778.4% in the 1st quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 1,440 shares during the last quarter. Leonteq Securities AG increased its position in Ultragenyx Pharmaceutical by 288.5% during the first quarter. Leonteq Securities AG now owns 1,795 shares of the biopharmaceutical company’s stock worth $38,000 after buying an additional 1,333 shares during the last quarter. Versant Capital Management Inc increased its position in Ultragenyx Pharmaceutical by 662.9% during the second quarter. Versant Capital Management Inc now owns 1,152 shares of the biopharmaceutical company’s stock worth $38,000 after buying an additional 1,001 shares during the last quarter. Danske Bank A S bought a new position in Ultragenyx Pharmaceutical during the third quarter valued at about $39,000. Finally, EverSource Wealth Advisors LLC raised its holdings in Ultragenyx Pharmaceutical by 573.0% during the first quarter. EverSource Wealth Advisors LLC now owns 2,167 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 1,845 shares in the last quarter. Institutional investors and hedge funds own 97.67% of the company’s stock.
Ultragenyx Pharmaceutical Stock Performance
Shares of NASDAQ:RARE opened at $15.30 on Friday. The stock’s 50-day moving average is $27.76 and its 200-day moving average is $24.97. The company has a market cap of $1.51 billion, a P/E ratio of -2.62 and a beta of 0.31. Ultragenyx Pharmaceutical Inc. has a 52-week low of $13.81 and a 52-week high of $39.89.
Analyst Upgrades and Downgrades
RARE has been the subject of several recent analyst reports. Guggenheim decreased their price target on Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a “buy” rating for the company in a research note on Tuesday, August 4th. Weiss Ratings raised Ultragenyx Pharmaceutical from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 9th. Morgan Stanley upped their target price on Ultragenyx Pharmaceutical from $67.00 to $74.00 and gave the stock an “overweight” rating in a research report on Friday, August 21st. JPMorgan Chase & Co. downgraded Ultragenyx Pharmaceutical from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $80.00 to $36.00 in a report on Thursday. Finally, HC Wainwright lowered their price target on Ultragenyx Pharmaceutical from $50.00 to $25.00 and set a “buy” rating on the stock in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $36.63.
View Our Latest Research Report on RARE
Ultragenyx Pharmaceutical News Summary
Here are the key news stories impacting Ultragenyx Pharmaceutical this week:
- Positive Sentiment: Several analysts still see substantial potential upside after the selloff. Barclays maintained an “overweight” rating with a $32 price target, while Jefferies, Citigroup, TD Cowen, Canaccord Genuity, Cantor Fitzgerald and HC Wainwright retained bullish ratings despite sharply reducing their targets.
- Positive Sentiment: Ultragenyx is evaluating “significant” cost reductions following the trial failure, which could help preserve cash and improve the company’s financial outlook. Investors are also focusing on its existing commercial rare-disease portfolio. Ultragenyx to weigh significant cost cuts as Angelman drug fails key study
- Positive Sentiment: Unusually heavy call-option activity and speculation that Ultragenyx could become an acquisition target provide potential—but highly speculative—support for the stock. Ultragenyx potential M&A target
- Neutral Sentiment: Analyst views are increasingly divided. Goldman Sachs lowered its target to $19 and moved to “neutral,” while Barclays remains “overweight” at $32. Jefferies and Citi kept “buy” ratings but reduced targets to $28. The wide range reflects uncertainty over Ultragenyx’s post-trial growth prospects.
- Negative Sentiment: RBC downgraded the company to “hold,” while Bank of America, JPMorgan, Wells Fargo, Baird, Evercore, William Blair and others also reduced ratings or targets. Baird and Evercore now see only limited upside, signaling diminished confidence in the pipeline.
- Negative Sentiment: The Angelman syndrome failure creates greater dependence on Ultragenyx’s existing products and other pipeline programs. The company is weighing the future of the program, adding uncertainty around research spending, revenue growth and long-term valuation. Ultragenyx Angelman syndrome trial failure
Insider Activity at Ultragenyx Pharmaceutical
In other news, Director Corazon (Corsee) D. Sanders sold 2,000 shares of the firm’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $25.05, for a total value of $50,100.00. Following the sale, the director owned 21,095 shares in the company, valued at approximately $528,429.75. This trade represents a 8.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Karah Parschauer sold 1,899 shares of the business’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $24.62, for a total transaction of $46,753.38. Following the transaction, the executive vice president directly owned 94,462 shares in the company, valued at $2,325,654.44. This trade represents a 1.97% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 5.20% of the company’s stock.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.
The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.
Featured Stories
- Five stocks we like better than Ultragenyx Pharmaceutical
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
